Browsing Tag
London Stock Exchange
330 posts
Jardine Matheson stock faces strategy test after A$3.4bn I-MED Radiology deal
Jardine Matheson is buying I-MED for A$3.4bn as radiology AI gains momentum. See why this healthcare deal matters now!
Why Apollo’s Bodycote proposal is another warning sign for UK industrial stocks
Apollo’s Bodycote proposal exposes the UK industrial valuation gap. Read why private equity is circling London-listed specialists.
BT Group raises dividend and rebases payout policy as Openreach fibre scale offsets revenue decline in FY26
BT Group raised its dividend and lifted profit 8%, yet BT.A fell 5% on a churn scare. The real test is whether the £3bn cash flow promise arrives.
Marks and Spencer (MKS) reports 23.8% profit drop to £671.4m as cyber incident bites but second half returns to growth
M&S profit fell 23.8% to £671.4m on a £131.3m cyber bill, yet Food surged 7% and the dividend rose 16.7%. The recovery case hinges on one fragile metric. Read more.
Is Helium One (HE1.L) finally moving from helium hype to proof?
Helium One has helium, licences and first gas. The harder test is whether HE1.L can secure a partner before dilution fears return.
ImmuPharma at 4p is a P140 licensing bet: What IMM retail investors should know
ImmuPharma targets a P140 licensing deal in 2026 with cash to H2 2028. Here is what IMM retail investors need to weigh before chasing the small-cap biotech.
AVCT entry at 86p is a bet on AVA6103: What Avacta Group investors should know
Avacta Group sets up a binary AVA6103 readout for late H2 2026. Here is what AVCT retail investors need to weigh before the data lands and runway runs.
Avacta FY25 puts AVCT on a clock: £16.9m cash, two Phase 1 reads, one shot
Avacta Group posts FY25 results with two clinical assets in trial, £16.9m cash, and AVA6103 data due in H2 2026 as AVCT trades near 52-week high.
Babcock (LSE: BAB) absorbs Type 31 charge but keeps FY27 outlook intact
Babcock’s Type 31 charge hurts profits, but cash flow and buybacks keep the turnaround alive. The execution risk now moves to FY27.
Intertek board opens door to EQT’s £60-a-share takeover bid as ITRK trades near 52-week high
Intertek says its strategy can create value. EQT is offering cash now. The £60-a-share bid turns patience into a boardroom test.